Heart Failure Clinical Trials in Fort Worth, Texas

7 studies are recruiting for heart failure in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

   Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CON-10301, Fort Worth, TX, Fort Worth, Texas

   Locations

   140 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06024746 on ClinicalTrials.gov

2. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

   This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Helios CR Inc - Fort Worth, Fort Worth, Texas

   Locations

   588 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06935370 on ClinicalTrials.gov

3. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

   Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Baylor Scott & White, Fort Worth, Texas

   Locations

   50 in total

   Run by

   Procyrion

   See if you can join NCT05677100 on ClinicalTrials.gov

4. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

   This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Helios CR Inc, Fort Worth, Texas

   Locations

   652 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06424288 on ClinicalTrials.gov

5. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Fort Worth, Texas

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

6. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor Scott & White Health, Fort Worth, Texas

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

7. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Baylor Scott White- All Saints- Fort Worth, Fort Worth, Texas

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov